During the last decade, it has become clear that the mammalian immune system is able to recognize and partially suppress nascent tumors. Human T cells specific to oncogenes and onco-fetal antigens are present in human cancer patients and their tumors. At the same time, molecular links between tumor-associated inflammation and tumor progression have been uncovered, providing an explanation for the long recognized epidemiological link between inflammation and cancer. The synopsis of these findings suggests a new interpretation of tumor immunity. It appears that antigen recognition or antigen-specific Tcell expansion at large is not as profoundly impaired in tumor patients as the correct polarization, the survival and the effector function of tumor-infiltrating T cells. This review will focus on pro-inflammatory cytokines likely to contribute to the deregulation of tumor-specific immunity and its consequences.
Introduction
Tumors often arise at the site of chronic inflammation. Examples include Helicobacter-associated gastric cancer, chronic colitis fueling the development of colon cancer and the chronic bronchitis of smokers lungs giving rise to lung cancer to list a few (Coussens and Werb, 2002; Lin and Karin, 2007) . Possible explanations for this epidemiological paradigm are multifold. Increased tissue regeneration during inflammatory responses to chronic damage or infection may provide a constant need for tissue regeneration. The resulting compensatory epithelial cell proliferation induced to regenerate lost or damaged tissues might lead to an increased chance of multiple mutations and a proliferative advantage for the cells carrying those mutations. In fact, the amount of cell loss and the subsequent regeneration correlate in mouse models of liver cancer to tumor growth (Maeda et al., 2005) . Also, radical oxygen species released by the inflammatory cells may increase the mutation rate in the proliferating epithelial stem cells. Angiogenesis provides another key condition for tumor formation and promotion with molecular links to inflammation. Although the tumor-promoting function of angiogenesis is now well established (Folkman, 2007) , remarkably one of pathologist's five hallmarks of inflammation for centuries has been rubor (lat. for redness) or angiogenesis. Therefore, before and even in the absence of any selective pressure exerted by an adaptive immune response, there are multiple valid explanations why tumor cells would originate, survive and thrive in a nutrient-rich environment like a chronically inflamed tissue.
The initial observations of antigen-specific recognition of human tumors by CD8T cells were made more than 20 years ago, followed by the cloning of the first definitive tumor antigens (Knuth et al., 1984; van der Bruggen et al., 1991) . Since then, it has become clear that the human immune system recognizes the antigenic profile of tumors relatively well (Van Der Bruggen et al., 2002; Jager et al., 2003) . The infiltration of cytotoxic T cells into tumor tissue is limited however, and T-cell infiltration into tumors correlates with an improved prognosis for the patient (Naito et al., 1998; Galon et al., 2006) . To overcome this limitation, therapies have been developed to expand the repertoire of tumorspecific T cells in patients, either by antigen-specific vaccines or by adoptive transfer of in vitro expanded cytotoxic T cells. However, even significant expansions of the numbers of circulating tumor-specific T cells do not often translate into long-term therapeutic benefits (Dudley et al., 2002) , even when the antigens recognized by the expanded and activated T cells are still expressed in the tumor (Rosenberg et al., 2005) . It is important to note that the induced or transferred T cells are sufficiently specific and sensitive to eliminate malignant cells in vitro but frequently fail to do so in the patient. In experimental mouse models, appropriate stimulation or resurrection of nascent immune surveillance appears capable of eliminating not only the tumor cells but also tumor-promoting stroma (Blankenstein, 2005) . The latter successes are mostly observed in small and early tumors, whereas well-established and clinically relevant stages of mouse tumors escape the same immune therapy.
We have recently suggested that the very regulation of tissue-regenerating inflammation might directly inhibit cytotoxic T cell-mediated destruction of tumor cells within the inflamed tissue (Langowski et al., 2007) . As a consequence, immune surveillance against tumors is largely prevented in the local environment by proinflammatory mediators such as interleukin (IL)-23 (Langowski et al., 2006) .
As described above, a solid body of evidence links increases in tumor incidence with inflammation. In addition, clinical and experimental findings also link tumor progression to the upregulation of pro-inflammatory molecules, particularly during the late stages of cancer progression and during tumor cachexia (Balkwill et al., 2005) . Several of the cytokines linked to tumorpromoting inflammation such as tumor necrosis factor-a (TNF-a), transforming growth factor-b (TGF-b), IL-6 and IL-23 are functionally linked to the newly discovered Th17 CD4 þ helper cell lineage.
In this review, we will attempt to summarize the tumorcentric cytokine network and its simultaneous influence on effector cell populations involved in the tumorassociated inflammatory response and immune surveillance of tumor development and progression (Figure 1 ).
Dual role for TNF-a in cancer?
Tumor necrosis factor-a is a trimeric cytokine produced by activated macrophages and pro-inflammatory T cells. TNF-a can stimulate both pro-and antiapoptotic signals in tumor cells, endothelial cells, macrophages and most other cells within the tumor microenvironment (Szlosarek et al., 2006) . TNF-a as well as IL-1 are essential effector cytokines for the initiation and maintenance of chronic inflammation in mouse models of immune-mediated disorders such as rheumatoid arthritis (Williams et al., 2000) . The relevance of this pathway for human disease is best exemplified in the success of anti-TNF-a therapies in inflammatory diseases (Feldmann and Maini, 2001 ). TNF-a also induces apoptosis in activated tumor-infiltrating T cells, and therefore may function to blunt the immune surveillance against tumors within the tumor itself. Although the pro-apoptotic effects of TNF-a spiked interest in its therapeutic utility, it requires higher concentrations than therapeutically achievable (Mocellin et al., 2005) . Most animal models and clinical studies revealed the pro-neoplastic functions of TNF-a rather than its pro-apoptotic functions on tumor cells.
Tumor necrosis factor-a produced by tumor cells or inflammatory cells may promote tumor survival via the induction of antiapoptotic genes controlled by nuclear factor-kB activation. Indeed, TNF-a has been demonstrated to promote tumorigenesis as TNF-a-deficient mice or mice treated with anti-TNF-a antibodies are largely protected from the chemical induction of skin papillomas (Moore et al., 1999; Scott et al., 2003) . TNF-a may also directly contribute to neoplastic transformation by stimulating production of genotoxic reactive oxygen species and nitric oxide (Szlosarek et al., 2006) .
In humans, higher concentrations of TNF-a are found in the serum of cancer patients compared to control subjects, and elevated TNF-a concentrations in the serum also correlate with decreased prognosis for the patients (Szlosarek and Balkwill, 2003) . Finally, TNF-a is closely associated with tumor-induced cachexia, an inflammatory multiorgan failure in the late stage of cancer patients, and with the inflammatory paraneoplastic syndromes associated with tumors like pancreatic cancer. Genetic polymorphisms conferring higher TNF-a production are associated with increased risk of a variety of human cancers (Szlosarek et al., 2006) . Excitingly, renal cell cancer patient treated in a phase II clinical study with anti-TNF-a antibodies experienced clinical benefits (Harrison et al., 2007) .
Inflammation control by TGF-b
Another key regulator of inflammatory processes tightly associated with chronic inflammation and cancer is TGF-b. Although considered to be primarily antiinflammatory, TGF-b contributes to the inflammatory milieu of tumor mediators and cell types facilitating tissue remodeling as well as direct local suppression of antigen-specific CD8T cell function.
Transforming growth factor-b is a pleiotropic cytokine that exerts effects on most cell types in a tumor thereby simultaneously impacting immunological and non-immunological processes. TGF-b activates a heterodimeric receptor pair of TGF-b receptors I and II (TbRI/II). Upon ligand binding, TbRI directly phosphorylates the transcription factors Smad2 and Smad3, which shuttle to the nucleus to induce transcription (Letterio, 2005) . TGF-b is released not only by a variety of cells in human and mouse tumors including macrophages, platelets and T cells (Kehrl et al., 1986; Roberts et al., 1986) , but also by the tumor cells themselves. Early in the development of cancer and in premalignant lesions, TGF-b plays a tumor suppressive function due to its inhibition of tumor cell growth. Genetic deletion of the TGF-b receptor in genetic mouse models for human cancer leads to increased tumor incidence and progression (Bierie and Moses, 2006) . Interestingly, ablation of TGF-b signaling in the tumor cells leads to an increased level of TGF-b in the tumor and increased number of TGF-b-producing CD11b þ GR-1 þ myeloid cells in the tumor stroma (Yang et al., 2008) . However, most human tumors thrive in the presence of large amounts of TGF-b while retaining the TGF-b signaling pathways. The exception appears to be malignancies of the gastrointestinal tract where mutations in either the TGF-b receptor or the Smads render the tumor cells insensitive to abundant TGF-b (Derynck et al., 2001) . Autocrine TGF-b regulation in tumor cells plays an important role during invasion, metastasis and epithelial-mesenchymal transition of tumor cells (Oft et al., 2002) . In addition, many of the tumors promoting effects of TGF-b involve paracrine regulation of inflammation and tissue remodeling. TGF-b modifies the activities of fibroblasts, endothelial cells, macrophages and T cells to engender an inflammatory milieu similar to chronic inflammatory diseases but deficient in cytotoxic cells such as CD8T cells and natural killer cells. TGF-b is one of the first proteins released from platelets after a vascular lesion, induces angiogenesis and is a potent chemoattractant for granulocytes and monocytes (Wahl et al., 1987; Brandes et al., 1991) ; TGF-b also limits the phagocytic and opsonizing activity of those innate responders. More importantly, although TGF-b promotes the development of Langerhans cells and dendritic cells from hematopoietic progenitors (Borkowski et al., 1996; Strobl et al., 1996) , it inhibits the maturation, antigen presentation and costimulation by both macrophages and dendritic cells (Li et al., 2006) . Such immature dendritic cells produce large amounts of TGF-b and might efficiently prime regulatory CD4 þ T cells (Treg). TGF-b is required for the development of Tregs, and TGF-b expression by Tregs is essential for their proliferation and function. Regulatory T cells are found in human tumors and their presence correlates again with a poorer prognosis (Curiel et al., 2004) . In a new twist of the development of helper T-cell lineages, it has become clear that pro-inflammatory IL-17-producing Th17T cells share a common path with regulatory T cells. Although the presence of TGF-b favors a regulatory fate of naive T cells, simultaneous presence of TGF-b and IL-6 fosters the differentiation of a proinflammatory T cell expressing IL-6 and IL-17 among other cytokines (Bettelli et al., 2006) . Given the tight association of IL-6 with tumor incidence and progression (see below), naive T cells entering an established tumor are more likely to be exposed to conditions favoring Th17 differentiation. Indeed, it has been shown that Th17 are present in large numbers in human and mouse tumors (Kryczek et al., 2007) .
Transforming growth factor-b not only restricts the proliferation of naive CD4 þ T cells by suppressing IL-2 production in T cells but also antagonizes both Th1 and Th2 effector differentiation (Li et al., 2006) . At the same time, however, TGF-b protects T cells from apoptosis during T-cell expansion and differentiation. In particular, TGF-b inhibits activation-induced cell death of T cells (Zhang et al., 1995) . Polyclonal T-cell activation in mice using activating anti-CD3 antibodies leads to widespread apoptosis of both CD4 and CD8 þ T cells in TGF-b1À/À mice (Chen et al., 2001) . Similarly to helper T cells, CD8 þ cytotoxic T cells are inhibited in their proliferation and differentiation by TGF-b (Wrzesinski et al., 2007). TGF-b inhibits the expression of cytokines like interferon-g (IFN-g) and cytotoxic effector molecules such as perforin, and also the exocytosis of the cytotoxic granules (Li et al., 2006) . Moreover, when stimulated with both IL-6 and TGF-b, CD8T cells not only cease expression of IFN-g and lose their cytotoxicity but are also induced to secrete IL-17 (Liu et al., 2007) . IFN-g induces major histocompatibility complex I in both dendritic cells and tumor cells; therefore, replacing IFN-g with IL-17 in the tumor milieu might have severe consequences for immune recognition and surveillance.
The pro-inflammatory cytokine IL-6 promotes tumor growth
Interleukin-6 engages the heterodimeric receptor complex of glycoprotein 130 (gp130) and IL-6 receptor-a (IL-6Ra). While gp130 is expressed in the signalreceiving cell, the IL-6Ra subunit can be either membrane bound or supplied as a soluble receptor (sIL-6Ra) by an accessory cell, via a process known as trans-signaling (Rose-John et al., 2006). IL-6 induces the phosphorylation of both STAT3 and STAT1. The involvement of both IL-6 and STAT3 in malignant cell survival and proliferation has been well documented in numerous experimental systems (Aggarwal et al., 2006; Rose-John et al., 2006) . Through the activation of genes involved in cell cycle progression and suppression of apoptosis, IL-6 can directly protect tumor cells from apoptosis. IL-6 has also been shown to act as an autocrine growth factor for tumors (Baffet et al., 1991) . IL-6 is essential in the initiation and maintenance of chronic inflammation of the colon (Atreya et al., 2000) . Trans-signaling of IL-6 is similarly essential for the development of inflammation-induced colon tumors (Becker et al., 2004) . Finally, antibody-mediated inhibition of IL-6 delays the development of chemically induced colitis-associated colon cancer (Becker et al., 2004) .
Interleukin-6 levels are elevated in the serum and tissue of cancer patients with multiple myeloma, renal cell, ovarian, colon, breast or prostate cancers. The IL-6 serum levels correlate negatively with the prognosis in breast and prostate cancer patients (Smith et al., 2001; Rao et al., 2006) . IL-6Ra is highly expressed on tumor cells, with some evidence for shedding of the sIL-6Ra to stimulate trans-signaling in cells not expressing IL-6Ra (Becker et al., 2004; Rose-John et al., 2006) . IL-6 may also be a cancer-predisposing genetic risk factor, with IL-6 promoter polymorphisms leading to higher IL-6 expression leading to a worse prognosis for colon cancer patients (Landi et al., 2003) .
In combination with TNF-a, IL-6 stimulates the expansion and cytotoxicity of naive CD8T cells in vitro (Sepulveda et al., 1999) ; however, IL-6Ra has been shown to be downregulated upon activation in naive and memory T cells (Betz and Muller, 1998) , suggesting that its potential stimulatory effect on tumor-infiltrating effector lymphocytes may be lost. Recently, however, it has become clear that IL-6 together with TGF-b is crucial for the induction of IL-17-producing Th17 helper cell lineage (Mangan et al., 2006; Wilson et al., 2007) . It remains to be tested how many of the effects of IL-6 in the regulation of tissue inflammation and cancer are dependent on the induction and subsequent control of this T-cell lineage. Importantly, it has been shown that the pro-inflammatory T helper cells continue to express both IL-17 and IL-6 (Becker et al., 2004; Langrish et al., 2005) . In inflammatory disease models, deficiency of IL-17 ameliorates the disease, deficiency of both IL-6 or IL-23, a cytokine controlling the activity of Th17 cells, protected animals from disease (Alonzi et al., 1998; Cua et al., 2003; Nakae et al., 2003) . While IL-6-deficient animals show a partial resistance to chemical-induced skin tumors (Ancrile et al., 2007) ; the absence of IL-23 renders animals completely protected from tumors (Langowski et al., 2006) .
Inflammation control by IL-23 and IL-12 in cancer
Interleukin-23 and IL-12 are closely related heterodimeric pro-inflammatory cytokines with similar structures, similar cellular sources and cellular targets but opposing functions. They are composed of a shared p40 subunit, structurally related to cytokine receptors, and a unique subunit, IL-23p19 or IL-12p35, structurally four-helix bundle cytokines . IL-12 uses the heterodimeric receptors IL-12Rb1 and IL-12Rb2, whereas IL-23 activates IL-12Rb-1/IL-23R dimers (Parham et al., 2002) . Like IL-12, IL-23 induces TYK2-and JAK2-mediated phosphorylation of the transcription factors STAT1, STAT3 and STAT5, the phosphorylation of STAT4 being to a lesser extent (Parham et al., 2002; Trinchieri, 2003) . The receptors for both IL-12 and IL-23 are primarily expressed on T, natural killer and natural killer T cells, with low levels present on monocytes, macrophages and dendritic cells. Both cytokines are produced primarily by activated antigen-presenting cells in response to bacterial products . Consequently, IL-12p40-deficient mice, lacking IL-12 and IL-23, are highly susceptible to numerous bacterial, fungal and parasite infections including Salmonella, Citrobacter, Cryptococcus and Leishmania species (Bowman et al., 2006) . For the response against most of these pathogens, IL-12-mediated responses are essential, whereas the IL-23 contribution is often only detected in the simultaneous absence of IL-12 . Instant lethal doses of Klebsiella or Citrobacter, however, require IL-23-mediated host responses in mice (Happel et al., 2003; Mangan et al., 2006) . Surprisingly, these susceptibilities have not been described for IL-12p40-or IL12Rb1-deficient humans who suffer exclusively from mycobacterial and salmonella infection but show normal resistance to most other pathogens, including viruses (Novelli and Casanova, 2004) .
IL-12 treatment in preclinical tumor models promotes immune surveillance against transplanted syngeneic tumors by inducing IFN-g-producing Th1 cells and the proliferation and cytotoxic activity of CD8 þ T cells and natural killer cells. IL-12-induced IFN-g is not only rate limiting for T-cell activity but also induces the expression of major histocompatibility complex I and thereby allows increased recognition of tumor antigens (Wong et al., 1984) . Tumor immune surveillance in mouse models is largely dependent on IFN-g-expressing T cells (Kaplan et al., 1998) . Similar experiments using IL-23 expressed in the transplanted tumor cell or systemically were equally efficient in rejecting syngeneic transplanted tumors (Lo et al., 2003) .
Interleukin-12 is therefore generally considered to promote antitumor effects, and cancer patients have been treated with recombinant IL-12 in several clinical studies (Atkins et al., 1997) . Dose-limiting toxicities were, however, observed before clinical benefits had been achieved. The toxicities appeared to be IFN-gassociated and were most likely the manifestations of a systemic immune response. Subsequent attempts combining IL-12 therapy with a peptide vaccine have so far not revealed enhanced clinical benefits in the IL-12 treatment arms (Cebon et al., 2003) .
The difference in IL-12 and IL-23 function against bacteria or tumors in mice and in man might be a reflection on the amount of infectious particles or the antigenic dose challenging the host defense. Most mouse models frequently use systemic exposure of the host to millions of colony-forming units of bacteria and viruses or injections with large numbers of tumor cells. Immune recognition of human tumors might, however, follow a quite different kinetic, with only limited antigen exposure at first. The majority of infections in human patients are similarly not characterized by initial exposure to large numbers of infectious particles.
However, there are also striking differences in the regulation of immune surveillance to tumors in either IL-12-or IL-23-deficient animals. IL-12 deficiency increases not only the incidence of tumors but also allows for rapid tumor growth in mice. In contrast, deficiency in IL-23 or the IL-23 receptor not only dramatically reduces tumor incidence but also reduces tumor growth of established tumors (Langowski et al., 2006) . In the local tumor microenvironment, IL-23 not only induces the hallmarks of chronic inflammation such as metalloproteases, angiogenesis and macrophage infiltration, but also reduces antitumor immunosurveillance by locally suppressing the presence of CD8T cells. In contrast, the absence of IL-12 leads to exacerbation of the myeloid-driven inflammation with a coincident lack of CD8 T cells (Langowski et al., 2006) . Interestingly, it is IL-23p19 and IL12p40 that are found to be overexpressed in the majority of human cancers, not IL-12p35.
In mouse models of autoimmune diseases, IL-23 induces chronic inflammation in part through the stimulation of innate myeloid effector cells and stromal activation, and many aspects of IL-23-dependent tissue inflammation can be recapitulated in the absence of T cells (Uhlig et al., 2006) .
However, IL-23 also controls the activity of Th17 T cells. Although Th17 develop from naive T cells under the influence of TGF-b and IL-6, they subsequently require IL-23 to suppress endogenous IL-10 and become proficient in their pro-inflammatory function (McGeachy et al., 2007) . This pro-inflammatory function orchestrates inflammatory tissue destruction by the adaptive immune system. The induction of IL-17 by IL-23 in tumors is an attractive prospect because IL-17 promotes angiogenesis in a variety of models and induces matrix metalloproteinases, two events that potentiate tumor growth (Numasaki et al., 2003) . In addition, IL-17 controls neutrophil chemotaxis, proliferation and maturation further fueling the innate immune activation (Kolls and Linden, 2004) . IL-17-producing CD8 and CD4 þ T cells have recently been reported to be widely present in human and mouse tumor microenvironments (Kryczek et al., 2007) . It has also been suggested that CD8 T cells expressing IL-17 largely lack cytotoxic capacity (Liu et al., 2007) . It is important to note that IL-23 can induce, independent of IL-17, angiogenic erythema, inflammation and keratinocyte hyperproliferation, phenocopying aspects of human psoriatic lesions (Chan et al., 2006) . Psoriatic disease does not correlate with increased incidence of malignancy (Rohekar et al., 2008) . The IL-23-mediated physiological changes in the skin, however, strikingly resemble the microenvironment observed in early malignant lesions
Conclusions
For decades, chronic inflammatory conditions have been observed in association with tumor incidence, tumor progression and detrimental prognosis in human cancer patients.
Only recently have we begun to understand the molecular mechanisms of how and why tumors occur more frequently in an inflammatory microenvironment or in an inflammation-plagued host. Pro-inflammatory cytokines are not surprisingly at the crossroad of this deregulation. As described above, several of these cytokines are highly expressed in human cancers (Figure 1 ) and do alter the adaptive immune response in ways that are simultaneously beneficial to tumor growth. Antigenspecific cytotoxicity, in particular by CD8T cells, is blunted, whereas the inflammation responses to the same tumor antigen are unaltered and even enhanced. Several of the cytokines essentially involved in the inflammatory regulation are either fueled by Th17 CD4 þ T cells or foster their development. Therapeutic expansion of the tumor antigen-specific immune response might therefore fail to eliminate the tumor but stimulate tumor-specific but non-cytotoxic inflammation.
It is tempting to speculate that the observed derailing of antitumor immunity into an inflammatory response is at its core, a defensive strategy of the tumor, selected for independently of the tumor cell transformation. Alternatively, it might be the mere result of, and the default reaction to, the expression of transforming oncogenes within the tumor cell. Third, the presence of mutant cell clones in an inflamed and regenerating tissue could simply be an unfortunate coincidence. Here, the tumor cell would take advantage of the improved cytokinemediated growth conditions for the nascent tumor, whereas the same cytokines such as IL-23 inhibit the immune-mediated tumor surveillance and tumor cell elimination.
It remains to be seen if anti-inflammatory molecules can deliver therapeutic benefit to patients suffering from large tumors, rather than serving merely a prophylactic role potentially preventing cancer occurrence.
